Cytokinetics, Incorporated CYTK Stock
Cytokinetics, Incorporated Price Chart
Cytokinetics, Incorporated CYTK Financial and Trading Overview
| Cytokinetics, Incorporated stock price | 63.11 USD |
| Previous Close | 38.89 USD |
| Open | 39.22 USD |
| Bid | 36.59 USD x 1500 |
| Ask | 37.55 USD x 1500 |
| Day's Range | 36.91 - 39.47 USD |
| 52 Week Range | 29.31 - 61.38 USD |
| Volume | 1.37M USD |
| Avg. Volume | 1.76M USD |
| Market Cap | 4.45B USD |
| Beta (5Y Monthly) | 0.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.55 USD |
CYTK Valuation Measures
| Enterprise Value | 3.92B USD |
| Trailing P/E | N/A |
| Forward P/E | -6.9072356 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 231.35953 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 203.877 |
| Enterprise Value/EBITDA | -7.045 |
Trading Information
Cytokinetics, Incorporated Stock Price History
| Beta (5Y Monthly) | 0.59 |
| 52-Week Change | -35.16% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 61.38 USD |
| 52 Week Low | 29.31 USD |
| 50-Day Moving Average | 33.21 USD |
| 200-Day Moving Average | 43.81 USD |
CYTK Share Statistics
| Avg. Volume (3 month) | 1.76M USD |
| Avg. Daily Volume (10-Days) | 1.55M USD |
| Shares Outstanding | 119.43M |
| Float | 118.83M |
| Short Ratio | 8.37 |
| % Held by Insiders | 0.71% |
| % Held by Institutions | 119.58% |
| Shares Short | 14.01M |
| Short % of Float | 15.29% |
| Short % of Shares Outstanding | 11.73% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -9856.30% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.12% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 19.22M USD |
| Revenue Per Share (ttm) | 0.17 USD |
| Quarterly Revenue Growth (yoy) | 89.09% |
| Gross Profit (ttm) | -338460992 USD |
| EBITDA | -556144000 USD |
| Net Income Avi to Common (ttm) | -615259008 USD |
| Diluted EPS (ttm) | -5.29 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 938.22M USD |
| Total Cash Per Share (mrq) | 7.86 USD |
| Total Debt (mrq) | 910.45M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 5.986 |
| Book Value Per Share (mrq) | -2.235 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -398000000 USD |
| Levered Free Cash Flow (ttm) | -241411120 USD |
Profile of Cytokinetics, Incorporated
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 350 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 624 3000 |
| Website | https://www.cytokinetics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 498 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Q&A For Cytokinetics, Incorporated Stock
What is a current CYTK stock price?
Cytokinetics, Incorporated CYTK stock price today per share is 63.11 USD.
How to purchase Cytokinetics, Incorporated stock?
You can buy CYTK shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Cytokinetics, Incorporated?
The stock symbol or ticker of Cytokinetics, Incorporated is CYTK.
Which industry does the Cytokinetics, Incorporated company belong to?
The Cytokinetics, Incorporated industry is Biotechnology.
How many shares does Cytokinetics, Incorporated have in circulation?
The max supply of Cytokinetics, Incorporated shares is 122.26M.
What is Cytokinetics, Incorporated Price to Earnings Ratio (PE Ratio)?
Cytokinetics, Incorporated PE Ratio is now.
What was Cytokinetics, Incorporated earnings per share over the trailing 12 months (TTM)?
Cytokinetics, Incorporated EPS is -6.3 USD over the trailing 12 months.
Which sector does the Cytokinetics, Incorporated company belong to?
The Cytokinetics, Incorporated sector is Healthcare.
Cytokinetics, Incorporated CYTK included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23593.1 USD — |
-0.09
|
4.43B USD — | 23567.86 USD — | 23665.15 USD — | — - | 4.43B USD — |
| US Tech Health Care IXHC | 1206.13 USD — |
-0.49
|
— — | 1203.49 USD — | 1210.54 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 11560.74 USD — |
-0.05
|
— — | 11548.2 USD — | 11595.66 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29011.05 USD — |
-0.09
|
— — | 28980.01 USD — | 29099.65 USD — | — - | — — |
| US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG | 3538.91 USD — |
-0.37
|
— — | 3529.1 USD — | 3552.53 USD — | — - | — — |
| US Tech Biotechnology NBI | 5809.25 USD — |
-0.59
|
— — | 5792.54 USD — | 5835.34 USD — | — - | — — |
- {{ link.label }} {{link}}